amlodipine has been researched along with Aging in 25 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pharmacodynamics and disposition of amlodipine, a dihydropyridine calcium antagonist, were compared between elderly and young patients with hypertension." | 7.68 | Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ( Abernethy, DR; Gutkowska, J; Winterbottom, LM, 1990) |
| "Amlodipine is a long-acting dihydropyridine-based calcium antagonist developed for use on a once-a-day basis." | 5.27 | The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload. ( Nayler, WG, 1988) |
| "This study in patients with moderate-to-severe hypertension assessed the efficacy and safety of adding hydrochlorothiazide (HCTZ) 12." | 5.16 | Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. ( Ammentorp, B; Christian Rump, L; Laeis, P; Volpe, M, 2012) |
| "Outpatients with mild hypertension treated with a low dose of amlodipine." | 3.77 | The correlation between the clinical laboratory data and the telomere length in peripheral blood leukocytes of Japanese female patients with hypertension. ( Arima, T; Maeda, T; Makino, N; Oyama, JI; Sasaki, M, 2011) |
| " The independent contribution of hypertension and the overactive renin-angiotensin system to soluble guanylyl cyclase subsensitivity was assessed after normalization of TGR's blood pressure by the Ca(2+)-channel blocker amlodipine or the angiotensin converting enzyme-inhibitor enalapril." | 3.70 | Contribution of the renin-angiotensin system to subsensitivity of soluble guanylyl cyclase in TGR(mREN2)27 rats. ( Behrends, S; Huser, L; Jacke, K; Lemmer, B; Witte, K, 2000) |
| "Pharmacodynamics and disposition of amlodipine, a dihydropyridine calcium antagonist, were compared between elderly and young patients with hypertension." | 3.68 | Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ( Abernethy, DR; Gutkowska, J; Winterbottom, LM, 1990) |
| " Amlodipine did not affect cardiac function in the young, and with chronic dosing decreased the heart rate by 3-5 bpm and the cardiac index by 0." | 2.72 | Sympatho-excitatory responses to once-daily dihydropyridines in young versus older hypertensive patients: amlodipine versus felodipine extended release. ( Coletta, E; Leenen, FH; White, R, 2006) |
| " The overall incidence of adverse effects were temporary and extremely limited (2%)." | 2.67 | Middle term evaluation of amlodipine vs nitrendipine: efficacy, safety and metabolic effects in elderly hypertensive patients. ( Feraco, E; Grandinetti, O, 1993) |
| "Amlodipine, a dihydropyridine calcium antagonist, was synthesized in an attempt to develop a compound with a pharmacokinetic profile characteristic of this class, which would also have an increased oral bioavailability and extended clearance time." | 2.38 | The pharmacokinetic profile of amlodipine. ( Abernethy, DR, 1989) |
| ": The risk of drug-drug interactions (DDIs) is elevated in aging people living with HIV (PLWH) because of highly prevalent age-related comorbidities leading to more comedications." | 1.56 | Aging does not impact drug--drug interaction magnitudes with antiretrovirals. ( Battegay, M; Cavassini, M; Courlet, P; Decosterd, L; Marzolini, C; Saldanha, SA; Stader, F; Stoeckle, M, 2020) |
| "Amlodipine was measured by liquid chromatography-tandem mass spectrometry." | 1.33 | Population analyses of amlodipine in patients living in the community and patients living in nursing homes. ( Kang, D; Schwartz, JB; Verotta, D, 2006) |
| "Mean amlodipine dose was 0." | 1.31 | Treatment of hypertensive children with amlodipine. ( Bunchman, TE; Flynn, JT; Smoyer, WE, 2000) |
| "Structural features of amlodipine give the molecule physicochemical and pharmacokinetic properties that are unique among calcium antagonists." | 1.28 | Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist. ( Abernethy, DR, 1991) |
| "Amlodipine is a long-acting dihydropyridine-based calcium antagonist developed for use on a once-a-day basis." | 1.27 | The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload. ( Nayler, WG, 1988) |
| " amlodipine, clearance tended to be decreased in elderly as compared with young patients with resulting prolongation in elimination half-life (64 +/- 20 vs." | 1.27 | Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. ( Abernethy, DR; Gutkowska, J; Lambert, MD, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.00) | 18.7374 |
| 1990's | 6 (24.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stader, F | 1 |
| Decosterd, L | 1 |
| Stoeckle, M | 1 |
| Cavassini, M | 1 |
| Battegay, M | 1 |
| Saldanha, SA | 1 |
| Marzolini, C | 1 |
| Courlet, P | 1 |
| Li, X | 1 |
| Ma, J | 1 |
| Xu, J | 1 |
| Zhu, D | 1 |
| Li, A | 1 |
| Che, Y | 1 |
| Chen, D | 1 |
| Feng, X | 1 |
| Carter, JM | 1 |
| Irving, AC | 1 |
| Bridges, JP | 1 |
| Jones, BR | 1 |
| Trenson, S | 1 |
| de Ceuninck, M | 1 |
| Lu, J | 1 |
| Liu, F | 2 |
| Chen, F | 1 |
| Jin, Y | 1 |
| Chen, H | 1 |
| Liu, D | 1 |
| Cui, W | 2 |
| Lu, JC | 1 |
| Zhang, HL | 1 |
| Han, M | 1 |
| Liu, DM | 1 |
| Yin, HN | 1 |
| Zhang, K | 1 |
| Du, J | 1 |
| Maeda, T | 1 |
| Oyama, JI | 1 |
| Sasaki, M | 1 |
| Arima, T | 1 |
| Makino, N | 1 |
| Volpe, M | 1 |
| Christian Rump, L | 1 |
| Ammentorp, B | 1 |
| Laeis, P | 1 |
| Civantos, B | 1 |
| Aleixandre, A | 1 |
| Abernethy, DR | 4 |
| Leenen, FH | 1 |
| Coletta, E | 1 |
| White, R | 1 |
| Kang, D | 1 |
| Verotta, D | 1 |
| Schwartz, JB | 1 |
| Palmieri, V | 1 |
| Pini, R | 1 |
| Chiara Cavallini, M | 1 |
| Io, K | 1 |
| Minatoguchi, S | 1 |
| Nishigaki, K | 1 |
| Ojio, S | 1 |
| Tanaka, T | 1 |
| Segawa, T | 1 |
| Matsuo, H | 1 |
| Watanabe, S | 1 |
| Hattori, A | 1 |
| Ueno, K | 1 |
| Ono, H | 1 |
| Hiei, K | 1 |
| Sato, H | 1 |
| Morita, N | 1 |
| Noda, T | 1 |
| Kato, T | 1 |
| Kawasaki, M | 1 |
| Takemura, G | 1 |
| Fujiwara, H | 1 |
| Mason, RP | 1 |
| Lorimer, AR | 1 |
| Anderson, JA | 1 |
| Laher, MS | 1 |
| Davies, J | 1 |
| Lazarus, JH | 1 |
| Taylor, SH | 1 |
| Sanghera, S | 1 |
| Grandinetti, O | 1 |
| Feraco, E | 1 |
| Spratt, KA | 1 |
| Jacke, K | 1 |
| Witte, K | 1 |
| Huser, L | 1 |
| Behrends, S | 1 |
| Lemmer, B | 1 |
| Flynn, JT | 1 |
| Smoyer, WE | 1 |
| Bunchman, TE | 1 |
| Gutkowska, J | 2 |
| Winterbottom, LM | 1 |
| Nayler, WG | 1 |
| Elliott, HL | 1 |
| Meredith, PA | 1 |
| Reid, JL | 1 |
| Faulkner, JK | 1 |
| Lambert, MD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination[NCT00923091] | Phase 3 | 2,689 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Baseline blood pressure was defined as the average values obtained at the randomization visit and at the visit prior to randomization (NCT00923091)
Timeframe: Baseline to week 10
| Intervention | mm HG (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -22.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -22.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | -23.0 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | -23.9 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | -23.8 |
| Olmesartan/Amlodipine 20mg/5mg | -20.5 |
| Olmesartan/Amlodipine 40mg/5mg | -21.2 |
| Olmesartan/Amlodipine 40mg/10mg | -22.1 |
(NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -3.3 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -4.1 |
(NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | -2.7 |
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25 | -3.8 |
(NCT00923091)
Timeframe: Week 26 to week 54
| Intervention | mm Hg (Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/25 Titrated to 40/10/25 | -11.9 |
(NCT00923091)
Timeframe: Baseline to week 10
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -33.2 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -33.7 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | -35.3 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | -35.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | -36.2 |
| Olmesartan/Amlodipine 20mg/5mg | -29.9 |
| Olmesartan/Amlodipine 40mg/5mg | -30.4 |
| Olmesartan/Amlodipine 40mg/10mg | -32.8 |
(NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -5.7 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -6.5 |
(NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | -4.5 |
| OLM/AML/HCTZ40/5/12.5mg Nonresponders Randomized to 40/5/25 | -6.7 |
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: baseline to week 10
| Intervention | Participants (Number) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | 177 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | 176 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | 197 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | 190 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | 179 |
| Olmesartan/Amlodipine 20mg/5mg | 144 |
| Olmesartan/Amlodipine 40mg/5mg | 155 |
| Olmesartan/Amlodipine 40mg/10mg | 166 |
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | Participants (Number) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | 29 |
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25 | 47 |
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | Participants (Number) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | 63 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | 137 |
1 review available for amlodipine and Aging
| Article | Year |
|---|---|
The pharmacokinetic profile of amlodipine.
Topics: Administration, Oral; Aging; Amlodipine; Angina Pectoris; Animals; Biological Availability; Calcium | 1989 |
5 trials available for amlodipine and Aging
| Article | Year |
|---|---|
Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination.
Topics: Adult; Aged; Aging; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Sympatho-excitatory responses to once-daily dihydropyridines in young versus older hypertensive patients: amlodipine versus felodipine extended release.
Topics: Adult; Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Blood Pressure; Body Wei | 2006 |
Double-blind comparison of amlodipine and nifedipine retard in the treatment of mild to moderate hypertension.
Topics: Adult; Aged; Aging; Amlodipine; Blood Pressure; Double-Blind Method; Drug Administration Schedule; F | 1994 |
Middle term evaluation of amlodipine vs nitrendipine: efficacy, safety and metabolic effects in elderly hypertensive patients.
Topics: Aged; Aging; Ambulatory Care; Amlodipine; Blood Pressure; Blood Pressure Determination; Female; Huma | 1993 |
A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects.
Topics: Adult; Aged; Aged, 80 and over; Aging; Amlodipine; Blood Pressure; Calcium Channel Blockers; Female; | 1988 |
19 other studies available for amlodipine and Aging
| Article | Year |
|---|---|
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly A | 2020 |
Puerarin and Amlodipine Improvement of D-Galactose-Induced Impairments of Behaviour and Neurogenesis in Mouse Dentate Gyrus: Correlation with Glucocorticoid Receptor Expression.
Topics: Aging; Amlodipine; Animals; Dentate Gyrus; Doublecortin Protein; Drug Therapy, Combination; Female; | 2017 |
The prevalence of ocular lesions associated with hypertension in a population of geriatric cats in Auckland, New Zealand.
Topics: Aging; Amlodipine; Animals; Antihypertensive Agents; Cat Diseases; Cats; Eye Diseases; Hypertension; | 2014 |
A calcified left ventricular mass.
Topics: Aged, 80 and over; Aging; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; At | 2014 |
Amlodipine and atorvastatin improve ventricular hypertrophy and diastolic function via inhibiting TNF-α, IL-1β and NF-κB inflammatory cytokine networks in elderly spontaneously hypertensive rats.
Topics: Aging; Amlodipine; Animals; Atorvastatin; C-Reactive Protein; Cardiomegaly; Diastole; Heart Ventricl | 2016 |
Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats.
Topics: Aging; Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiom | 2009 |
The correlation between the clinical laboratory data and the telomere length in peripheral blood leukocytes of Japanese female patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Blotting, Southern; Crea | 2011 |
Blood pressure and alpha-vascular reactivity in hypertensive rats treated with amlodipine and dietary Ca.
Topics: Adrenergic alpha-Agonists; Aging; Amlodipine; Animals; Antihypertensive Agents; Azepines; Blood Pres | 2004 |
Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist.
Topics: Adsorption; Adult; Aged; Aged, 80 and over; Aging; Amlodipine; Calcium Channel Blockers; Drug Intera | 1991 |
Population analyses of amlodipine in patients living in the community and patients living in nursing homes.
Topics: Aged; Aged, 80 and over; Aging; Alcohol Drinking; Algorithms; Amlodipine; Calcium Channel Blockers; | 2006 |
Pulsology reloaded: commentary on similar effects of treatment on central and brachial blood pressure in older hypertensive subjects.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Brach | 2007 |
Effects of benidipine and some other calcium channel blockers on the prognosis of patients with vasospastic angina. Cohort study with evaluation of the ergonovine coronary spasm induction test.
Topics: Adult; Aged; Aging; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Cohort Studies; Coronary | 2007 |
Probing membrane bilayer interactions of 1,4-dihydropyridine calcium channel blockers. Implications for aging and Alzheimer's disease.
Topics: Aged; Aging; Alzheimer Disease; Amlodipine; Brain Chemistry; Calcium Channel Blockers; Cell Membrane | 1994 |
Sex- and age-related antihypertensive effects of amlodipine.
Topics: Aged; Aging; Amlodipine; Antihypertensive Agents; Edema; Female; Humans; Hypertension; Male; Middle | 1997 |
Contribution of the renin-angiotensin system to subsensitivity of soluble guanylyl cyclase in TGR(mREN2)27 rats.
Topics: Aging; Amlodipine; Analysis of Variance; Animals; Animals, Genetically Modified; Aorta, Thoracic; Bl | 2000 |
Treatment of hypertensive children with amlodipine.
Topics: Adolescent; Adult; Aging; Amlodipine; Antihypertensive Agents; Blood Pressure; Child; Child, Prescho | 2000 |
Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition.
Topics: Administration, Oral; Adult; Aged; Aging; Amlodipine; Atrial Natriuretic Factor; Blood Pressure; Cal | 1990 |
The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload.
Topics: Aging; Amlodipine; Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Cardiomegaly; Coronar | 1988 |
Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics.
Topics: Adult; Aged; Aging; Amlodipine; Blood Pressure; Calcium Channel Blockers; Female; Half-Life; Hormone | 1988 |